Literature DB >> 26641933

Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Michael B Battles1, Johannes P Langedijk2, Polina Furmanova-Hollenstein2, Supranee Chaiwatpongsakorn3, Heather M Costello3, Leen Kwanten4, Luc Vranckx4, Paul Vink5, Steffen Jaensch5, Tim H M Jonckers6, Anil Koul4, Eric Arnoult7, Mark E Peeples3,8, Dirk Roymans4, Jason S McLellan1.   

Abstract

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly. Therapeutic small molecules have been developed that bind the RSV F glycoprotein and inhibit membrane fusion, yet their binding sites and molecular mechanisms of action remain largely unknown. Here we show that these inhibitors bind to a three-fold-symmetric pocket within the central cavity of the metastable prefusion conformation of RSV F. Inhibitor binding stabilizes this conformation by tethering two regions that must undergo a structural rearrangement to facilitate membrane fusion. Inhibitor-escape mutations occur in residues that directly contact the inhibitors or are involved in the conformational rearrangements required to accommodate inhibitor binding. Resistant viruses do not propagate as well as wild-type RSV in vitro, indicating a fitness cost for inhibitor escape. Collectively, these findings provide new insight into class I viral fusion proteins and should facilitate development of optimal RSV fusion inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26641933      PMCID: PMC4731865          DOI: 10.1038/nchembio.1982

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  49 in total

1.  Phaedra, a protocol-driven system for analysis and validation of high-content imaging and flow cytometry.

Authors:  Frans Cornelissen; Miroslav Cik; Emmanuel Gustin
Journal:  J Biomol Screen       Date:  2012-01-10

Review 2.  The cost effectiveness of palivizumab: a systematic review of the evidence.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  J Med Econ       Date:  2010       Impact factor: 2.448

3.  Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.

Authors:  Janet L Douglas; Marites L Panis; Edmund Ho; Kuei-Ying Lin; Steve H Krawczyk; Deborah M Grant; Ruby Cai; Swami Swaminathan; Xiaowu Chen; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

5.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13

8.  Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein.

Authors:  Patrick J Branigan; Changbao Liu; Nicole D Day; Lester L Gutshall; Robert T Sarisky; Alfred M Del Vecchio
Journal:  Virol J       Date:  2005-07-13       Impact factor: 4.099

Review 9.  Strategic priorities for respiratory syncytial virus (RSV) vaccine development.

Authors:  L J Anderson; P R Dormitzer; D J Nokes; R Rappuoli; A Roca; B S Graham
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  50 in total

1.  Inhibitory Effect of PIK-24 on Respiratory Syncytial Virus Entry by Blocking Phosphatidylinositol-3 Kinase Signaling.

Authors:  Li-Feng Chen; Wei-Bin Xu; Yue-Yue Li; Neng-Hua Chen; Ding Luo; Qiao-Yun Song; Wei Tang; Zhi-Gang Huang; Yao-Lan Li; Zhong Liu; Man-Mei Li
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Authors:  Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

3.  Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex.

Authors:  Alberto Jiménez-Somarribas; Shuli Mao; Jeong-Joong Yoon; Marco Weisshaar; Robert M Cox; Jose R Marengo; Deborah G Mitchell; Zachary P Morehouse; Dan Yan; Ivan Solis; Dennis C Liotta; Michael G Natchus; Richard K Plemper
Journal:  J Med Chem       Date:  2017-03-13       Impact factor: 7.446

4.  Computational chemistry at Janssen.

Authors:  Herman van Vlijmen; Renee L Desjarlais; Tara Mirzadegan
Journal:  J Comput Aided Mol Des       Date:  2016-12-19       Impact factor: 3.686

5.  Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors.

Authors:  Xiufang Zheng; Lisha Wang; Baoxia Wang; Kun Miao; Kunlun Xiang; Song Feng; Lu Gao; Hong C Shen; Hongying Yun
Journal:  ACS Med Chem Lett       Date:  2016-04-20       Impact factor: 4.345

6.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.

Authors:  Rameshwar U Kadam; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-21       Impact factor: 11.205

7.  Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus.

Authors:  Nicole Pribut; Thomas M Kaiser; Robert J Wilson; Edgars Jecs; Zackery W Dentmon; Stephen C Pelly; Savita Sharma; Perry W Bartsch; Pieter B Burger; Soyon S Hwang; Thalia Le; Julien Sourimant; Jeong-Joong Yoon; Richard K Plemper; Dennis C Liotta
Journal:  ACS Infect Dis       Date:  2020-04-20       Impact factor: 5.084

8.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

Review 9.  Therapeutic Potential of Spirooxindoles as Antiviral Agents.

Authors:  Na Ye; Haiying Chen; Eric A Wold; Pei-Yong Shi; Jia Zhou
Journal:  ACS Infect Dis       Date:  2016-05-05       Impact factor: 5.084

10.  Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Authors:  Michael N Ha; Sébastien Delpeut; Ryan S Noyce; Gary Sisson; Karen M Black; Liang-Tzung Lin; Darius Bilimoria; Richard K Plemper; Gilbert G Privé; Christopher D Richardson
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.